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Abstract Memory loss in Alzheimer’s disease (AD) is attributed to pervasive weakening and loss
of synapses. Here, we present findings supporting a special role for excitatory synapses connecting
pyramidal neurons of the hippocampus and cortex with fast-spiking parvalbumin (PV) interneurons
that control network excitability and rhythmicity. Excitatory synapses on PV interneurons are
dependent on the AMPA receptor subunit GluA4, which is regulated by presynaptic expression of
the synaptogenic immediate early gene NPTX2 by pyramidal neurons. In a mouse model of AD
amyloidosis, Nptx2-/- results in reduced GluA4 expression, disrupted rhythmicity, and increased
pyramidal neuron excitability. Postmortem human AD cortex shows profound reductions of NPTX2
and coordinate reductions of GluA4. NPTX2 in human CSF is reduced in subjects with AD and
shows robust correlations with cognitive performance and hippocampal volume. These findings
implicate failure of adaptive control of pyramidal neuron-PV circuits as a pathophysiological
mechanism contributing to cognitive failure in AD.
DOI: 10.7554/eLife.23798.001
Introduction
The cause of memory loss in Alzheimer’s disease remains an important unknown that negatively
impacts therapeutics development (De Strooper and Karran, 2016). Amyloid Aß that accumulates
in human brain reduces excitatory synaptic function (Shankar et al., 2008) and mouse models of Aß
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amyloidosis document that Aß causes weakening and loss of excitatory synapses (Kamenetz et al.,
2003; Um et al., 2013). Aß also increases pyramidal neuron excitability consequent to down-regula-
tion of voltage sensitive ion channel Nav1.1 in PV inhibitory interneurons (Verret et al., 2012). How-
ever, human studies indicate amyloid accumulation typically precedes cognitive failure by many
years (Jack and Holtzman, 2013). Moreover, case studies report patients who were cognitively nor-
mal at death yet show pronounced Aß plaque and neurofibrillary tangles consistent with AD
(Driscoll and Troncoso, 2011). Mouse models of Aß amyloidosis show cognitive improvement fol-
lowing inhibition of Aß generating enzymes or amyloid reducing therapies (Comery et al., 2005;
Kimura et al., 2010; Townsend et al., 2010), yet similar successes have not been reported in human
trials. This discrepancy highlights the need for expanded understanding of cognitive failure in human
AD.
We focused attention on carefully archived human brain and cerebrospinal fluid samples to assess
mechanisms important for cognitive function in AD. Extending from observations of altered brain
activity and its possible contribution to human AD progression (Buckner et al., 2009,
Buckner et al., 2005) we assayed proteins of the class of cellular immediate early genes (IEGs),
which mediate activity-dependent plasticity important for memory function and can be assayed in
human post-mortem tissue (Wu et al., 2011). Here, we report that Neuronal Pentraxin 2 (NPTX2;
also termed Narp and NP2) is down-regulated in brain of human subjects with Alzheimer’s disease
(AD). NPTX2 is a member of a family of ‘long’ Neuronal Pentraxins that includes Neuronal Pentraxin
1 (NPTX1) and Neuronal Pentraxin Receptor (NPTXR). NPTX1, NPTX2 and NPTXR form disulfide-
linked, mixed NPTX complexes that traffic to the extracellular surface at excitatory synapses
(Xu et al., 2003) where they bind AMPA type glutamate receptors and contribute to multiple forms
of developmental and adult synaptic plasticity (Chang et al., 2010; Cho et al., 2008; Gu et al.,
2013; Lee et al., 2017; O’Brien et al., 2002, 1999; Pelkey et al., 2015, 2016). NPTXs directly bind
AMPA type glutamate receptors and can act in ‘trans’ as presynaptic factors that induce postsynap-
tic excitatory synapses (Lee et al., 2017; O’Brien et al., 2002, 1999; Sia et al., 2007). NPTX2
expressed by pyramidal neurons and secreted by axon terminals uniquely mediates activity-depen-
dent strengthening of pyramidal neuron excitatory synapses on GABAergic PV-interneurons
(Chang et al., 2010). This adaptive strengthening of the pyramidal neuron-PV interneuron synapse
mediates homeostatic scaling of the circuit, a process implicated in the ability of circuits to encode
information (Turrigiano, 2012). We examined the consequence of NPTX2 reduction in a mouse
model of AD and found that amyloidosis together with Nptx2-/- results in a synergistic reduction of
inhibitory circuit function in conjunction with a reduction of the AMPA type glutamate receptor
GluA4. GluA4 is preferentially expressed in PV-interneurons at excitatory synapses where it co-local-
ized with NPTX2 (presynaptic source) (Chang et al., 2010) and confers rapid channel inactivation
(Angulo et al., 1997; Geiger et al., 1995) that is essential for fast spiking and contributions of PV
interneurons to hippocampal circuit rhythmicity and memory (Fuchs et al., 2007). Nptx2-/- depen-
dent reduction of GluA4 was previously described in a different mouse model (Nptx2-/-; Nptxr-/-)
where analysis suggested NTPX2 is required to bind and stabilize postsynaptic expression of GluA4
in PV-interneurons in conditions of altered activity (Pelkey et al., 2015, 2016). In human brain
GluA4 is also selectively expressed in PV-INs and is reduced in AD brain regions where levels corre-
late within samples to NPTX2. This suggests that NPTX2 reduction in human AD brain is linked to
disruption of pyramidal neuron-PV interneuron circuits. To assess the relation between NPTX2 and
cognitive function in human subjects, we determined that NPTX2 is present in CSF and levels are
representative of brain NPTX2 since CSF NPTX2 discriminates clinically defined AD compared to
age-matched controls. Importantly, NPTX2 levels in AD subjects correlated with cognitive perfor-
mance employing comprehensive psychometric tests including the Dementia Rating Scale, and sur-
passed the performance of other CSF markers including Aß42, tau and p-tau. NPTX2 levels also
correlated with MRI measures of hippocampal volume, which is considered a marker of neurodegen-
eration and is linked to cognitive decline (Jack et al., 2010; Weiner et al., 2015). NPTX2 is not
down-regulated in a widely used mouse amyloidosis model and is distinct from other CSF markers
attributed to neurodegeneration including tau and p-tau in that NPTX2 is an indicator of specific
rather than general excitatory synapses. Studies support the hypothesis that NPTX2 down-regulation
results in disruption of pyramidal neuron-PV interneuron circuits that are important for brain rhyth-
micity and homeostasis of excitability, and represents a previously unrecognized mechanism impor-
tant for human cognitive dysfunction and progression in AD.
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Results
NPTX2 is reduced in human AD and Down syndrome brain
NPTX2 protein was assayed by western blot (WB) in human brain from individuals with pathologically
confirmed late onset Alzheimer’s disease (AD) versus age-matched controls (Figure 1A and B, Fig-
ure 1—figure supplement 1 and Figure 1—source data 1). NPTX2 was reduced in all cortical
regions including those areas that display prominent classical neuropathological changes in AD, as
well as areas that are typically less affected such as occipital cortex. Hippocampus was not available
for many cases and could not be systematically examined. Reductions of NPTX2 were evident
whether referenced to actin (Figure 1—figure supplement 1A) or PSD95 (Figure 1B); the latter indi-
cating that NPTX2 down-regulation is distinct from a general reduction of excitatory synaptic
markers. Nptx2 mRNA was also prominently reduced in assayed regions (Figure 1C). Neuronal Pen-
traxin 1 (NPTX1) and Neuronal Pentraxin Receptor (NPTXR) were not reduced in the same brain sam-
ples (Figure 1D and E). To further assess the specificity of NPTX2 down-regulation we determined
that other IEGs including Arc and Egr-1 were not reduced (Figure 1—figure supplement 1B).
NPTX2 was not reduced in brain of subjects who were cognitively normal at death but whose brains
exhibit pathology typical of AD including Aß plaque and tangles [asymptomatic AD (ASYMAD) or
preAD (Codispoti et al., 2012; Driscoll et al., 2006; Driscoll and Troncoso, 2011) (Figure 1F and
G, and Figure 1—source data 1). Nptx2 protein and mRNA were also reduced in middle frontal
gyrus of Down syndrome (DS) subjects aged 19 y/o to 40 y/o compared to age matched controls
(Figure 1H to 1J and Figure 1—source data 2). DS individuals exhibit a high risk for AD after the
age of 40 (Zigman and Lott, 2007). Nptx2 protein (normalized to actin) and mRNA were similarly
reduced in older DS individuals with AD (Figure 1—figure supplement 2 and Figure 1—source
data 3).
A microRNA mechanism of NPTX2 down-regulation in human AD brain
We examined determinants of Nptx2 mRNA down-regulation in human brain. Nptx2 transcription is
regulated by methylation of flanking genomic sequences in pancreatic cells (Zhang et al., 2012),
however, Nptx2 methylation assayed by pyrosequencing was low in human brain and not different
between control and AD subjects (Figure 2—figure supplement 1). Furthermore, Nptx2 pre-mRNA
expression was not different between control and AD subjects (Figure 2A) suggesting Nptx2 tran-
scription is maintained in AD, and that reduced mRNA is consequent to reduced pre-mRNA process-
ing (ex. splicing) or mRNA stability. IEGs are targets of miRNA control (Huang et al., 2012) and
TargetScan predicted several candidate miRNAs that target Nptx2 3’ UTR (Figure 2B). We deter-
mined that miR-1271 as well as its originating pri-miR, pre-mRNA and mRNA [miR-1271 is generated
from intron of human gene Arl10 (ADP-ribosylation factor-like 10)] were increased in AD frontal cor-
tex where levels in individual samples correlated with Nptx2 mRNA (Figure 2C, and Figure 2—fig-
ure supplement 2A). Analysis of AD precuneus gyrus detected similar preservation of Nptx2 pre-
mRNA (Figure 2—figure supplement 2B), and increases of pri-miR-1271, Arl10 pre-mRNA and
mRNA, as well as increases of miR-182 (Figure 2—figure supplement 2C). For comparison, we
examined frontal cortex of DS cases and confirmed up-regulation of the triploid miR-155 (positive
control) together with increases in miR-96 and miR-182 (Figure 2D). miR-96, miR-182 and miR-1271
target the same sequence in Nptx2 3’UTR (Figure 2E). We confirmed in heterologous cells that all
three miRs reduce expression of a luciferase fusion encoding human Nptx2 3’UTR compared to a
point mutant 3’ UTR that prevents miR targeting (Figure 2—figure supplement 2E–F). miRs
expressed as pri-miRs by lentivirus in cultured mouse cortical neurons reduced native mouse NPTX2
protein expression (Figure 2F to 2 H). miR-96 was most effective and additionally reduced Nptx2
mRNA but not pre-mRNA. Caveats for these experiments include the artificially high level of lentivi-
ral miR expression, possible species differences in the response, and the acuteness of the manipula-
tion relative to human disease. Nevertheless, these studies indicate that NPTX2 down-regulation in
human AD and DS brain occurs consequent to dysregulation of mRNA after transcription and sug-
gest a role for miR mechanisms.
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Figure 1. NPTX2 levels are reduced in human postmortem AD brain and DS brain, but not in ASYMAD brain. (A,B,D and E) Representative western
blot images (A) and quantification of NPTX2 (B), NPTX1 (D) and NPTXR (E) normalized to PSD95 in the frontopolar cortex (FPC), precuneus (PCU),
occipital gyrus (OCC), middle frontal gyrus (MFG), middle temporal gyrus (MTG) and parietal gyrus (PAR) from controls and AD subjects. NPTX2 is
down-regulated in all assayed brain regions of AD individuals. FPC: control, n = 7; AD, n = 8. PCU: control, n = 15; AD, n = 19. OCC: control, n = 7; AD,
n = 7. MFG: control, n = 9; AD, n = 16. MTG: control, n = 10; AD, n = 18. PAR: control, n = 5; AD, n = 5. (C) Nptx2 mRNA is reduced in AD brain. FPC:
control, n = 9; AD, n = 16. PCU: control, n = 7; AD, n = 6. (F,G) Western blot assays reveal no significant change of NPTX2 expression in MFG from
subjects with asymptomatic AD (ASYMAD). Control, n = 8; ASYMAD, n = 10. (H, I) Western blot assays show significant reduction of NPTX2 in MFG of
individuals with Down syndrome (DS). Control, n = 6; DS, n = 6. (J) Nptx2 mRNA is reduced in MFG of individuals with DS. Control, n = 5; DS, n = 5.
*p<0.05, **p<0.01, ***p<0.001 by two-tailed t test. Data represent mean ± SEM.
DOI: 10.7554/eLife.23798.002
The following source data and figure supplements are available for figure 1:
Source data 1. Clinical and histopathological information of ASYMAD and AD individuals for brain analysis.
DOI: 10.7554/eLife.23798.003
Source data 2. Information of individuals with Down syndrome for brain analysis.
DOI: 10.7554/eLife.23798.004
Source data 3. Information of individuals with Down syndrome and Alzheimer’s disease for brain analysis.
DOI: 10.7554/eLife.23798.005
Figure 1 continued on next page
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Nptx2 ko and Aß amyloidosis synergistically disrupt hippocampal
rhythmicity
NPTX2 is not reduced in brain of 6 month old APPswe/PS1DE9 mice (here termed hAPP)
(Borchelt et al., 1997) (Figure 3—figure supplement 1). To assess the possible impact of NPTX2
down-regulation in human AD brain, we created a mouse model that combines amyloidosis
(APPswe/PS1DE9; here termed hAPP) and Nptx2-/-. Amyloidosis in a similar mouse model increases
hippocampal excitability by reducing excitability of PV-interneurons (Palop et al., 2007;
Verret et al., 2012). Accordingly, we considered the possibility that loss of NPTX2 would further
reduce PV neuron function. We prepared acute hippocampal slices from 3–4 month old mice and
recorded extracellular field potentials from stratum pyramidale of CA3 from WT, Nptx2-/-, hAPP and
hAPP/Nptx2-/-. Spontaneous sharp wave ripples (SWR) were evident in all four groups (Figure 3—
figure supplement 2A–2D). SWR are spontaneous oscillatory currents that are dependent on PV-
interneuron function (Csicsvari et al., 1999; Ellender et al., 2010) and reflect the near synchronous
firing of pyramidal neuron ensembles. SWRs occurred at a significantly higher incidence, but with a
lower peak frequency, in hAPP/Nptx2-/- mice (Figure 3—figure supplement 2E–2F). We next moni-
tored gamma oscillations induced by bath-application of carbachol (Fisahn et al., 1998). Gamma
oscillations are field potentials recorded near the soma of pyramidal neurons and reflect the synchro-
nized inhibitory currents created by PV interneuron synaptic drive (Buzsa´ki and Wang, 2012). In
both WT and Nptx2-/- mice, gamma oscillations were observed with a peak frequency of 30 to 40 Hz
(Figure 3A and B). hAPP mice displayed a regular gamma-like rhythm, but at a lower frequency
(Figure 3C). hAPP/Nptx2-/- exhibited even slower ‘gamma’ oscillation with significantly reduced
peak power (Figure 3D to 3F). Additionally, rhythmicity was disrupted by prominent hypersynchro-
nous bursts (Figure 3D) indicative of increased network excitability.
Nptx2 ko and Aß amyloidosis synergistically disrupt hippocampal
GluA4 expression
We sought evidence for a specific role for Nptx2-/- on pyramidal neuron-PV interneuron function in
hAPP/Nptx2-/- mice. NPTX2 is required for homeostatic up regulation of GluA4 at excitatory synap-
ses on PV interneurons in response to increased pyramidal neuron activity (Chang et al., 2010).
GluA4 expression is not substantially altered in brain of NPTX2-/- mice (Figure 3G), however, GluA4
is markedly reduced in Nptx2-/-/Nptxr-/- mice (Pelkey et al., 2015, 2016). Since NPTXR is required
for mGluR-LTD (Cho et al., 2008), Nptxr-/- presumably increases pyramidal neuron excitability and
demand for NPTX2 to bind and stabilize GluA4. We monitored GluA4 expression and found a
marked reduction in hAPP/Nptx2-/- compared to WT control or hAPP (Figure 3H). Neither Nptx2-/-
alone (Figure 3G) (Pelkey et al., 2015, 2016) nor hAPP alone (Figure 3H) reduced GluA4 expres-
sion indicating that GluA4 reduction in hAPP/Nptx2-/- represents an emergent phenotype that
impacts PV interneuron function. While there are important limitations of hAPP/Nptx2-/- mice as a
model of AD including supra pathophysiological levels of Aß and complete deletion of NPTX2, these
studies identify GluA4 expression and effects on inhibitory circuit function as consequences of the
combined action of amyloidosis and NPTX2 down-regulation.
GluA4 expression correlates with NPTX2 in both aged human control
and AD subjects
As in mouse brain, GluA4 expression is selectively enriched in PV-interneurons in human brain
(Figure 4A). We examined GluA4 expression in multiple brain regions in both AD subjects and age-
matched controls. GluA4 expression was reduced in AD brain regions including precuneus and
medial frontal gyri (Figure 4B and C). The precuneus gyrus (Brodmann Area 7) resides in the parietal
cortex and is part of the ‘default network’ with strong connections to the hippocampus
Figure 1 continued
Figure supplement 1. Immediate early gene expression in human postmortem AD brain.
DOI: 10.7554/eLife.23798.006
Figure supplement 2. NPTX2 levels are reduced in human postmortem DS-AD brain.
DOI: 10.7554/eLife.23798.007
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(Buckner et al., 2008; Greicius et al., 2004; Vincent et al., 2006) and is notable for high levels of
amyloid detected by PET in AD subjects and some aged control individuals (Sperling et al., 2009).
The histopathology of the precuneus gyrus in AD is not different from surrounding brain regions
(Nelson et al., 2009). Interesting, when GluA4 expression was evaluated separately in controls and
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Figure 2. miRNAs dysregulation and NPTX2 down-regulation in AD brains. (A) Nptx2 pre-mRNA levels are identical in frontopolar cortex (FPC) of AD
subjects and control. Control, n = 9; AD, n = 16. (B) microRNAs predicted to bind with Nptx2 3’UTR by TargetScan. (C) Taqman assays show miR-182
and miR-1271 are increased in FPC of AD individuals. Control, n = 9; AD, n = 16. *p<0.05, **p<0.01 by two-tailed t test. (D) miR-96, miR-152 and miR-
182 are up-regulated in individuals with Down syndrome (DS). Triploid miR-155 served as positive control. Control, n = 14; DS, n = 18. *p<0.05,
**p<0.01, ***p<0.001 by two-tailed t test. (E) miR-96, miR-182 and miR-1271 target the same sequence in Nptx2 3’UTR. (F–H) Cultured mouse cortical
neurons are transduced with lentivirus expressing nontargeting miRNA (LV-NT) or miR-96, miR-1271 and miR-182. (F) Expression of miR-96, miR-1271
and miR-182 reduce NPTX2 protein level. (G) miR-96 reduces Nptx2 mRNA. (H) Nptx2 pre-mRNA is preserved by miR-96 and miR-1271 expression.
n = 5 wells from three independent culture except n = 4 wells for LV-NT group in Figure 2G. *p<0.05, ***p<0.001 by nonparametric one way ANOVA
with Tukey post hoc test. Data represent mean ± SEM.
DOI: 10.7554/eLife.23798.008
The following figure supplements are available for figure 2:
Figure supplement 1. Methylation of Nptx2 promoter in human brain.
DOI: 10.7554/eLife.23798.009
Figure supplement 2. Nptx2 mRNA is targeted by miRNAs that are upregulated in AD brain.
DOI: 10.7554/eLife.23798.010
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Figure 3. Circuit Rhythmicity and GluA4 expression are disrupted in hAPP/Nptx2-/- mice. (A–D) Example extracellular field potentials (i) with hatched
area shown on an expanded time base (ii) for WT (A), Nptx2-/- (B), hAPP (C), and hAPP/Nptx2-/- (D) mice. For hAPP/Nptx2-/- trace, grey trace in (ii)
shows trace on expanded time base and the black trace shows expanded voltage axis to show gamma-like oscillations nested within population spikes.
(E) Power spectra for WT, Nptx2-/-, hAPP, and hAPP/Nptx2-/- mice, taken from 400 s of recording, normalised to the power between 3 and 300 Hz. (F)
The normalised power of gamma-like oscillations was significantly reduced in hAPP/Nptx2-/- mice (z-score; WT, 5.1 ± 0.73; Nptx2-/-, 3.8 ± 0.63; hAPP,
3.9 ± 0.79; hAPP/Nptx2-/-, 1.7 ± 0.68; p=0.0199, One-way ANOVA). **, p<0.01 vs WT, post-hoc multiple comparisons test. (G) GluA4 expression is not
altered in 6 month-old Nptx2-/- mouse cortex. n = 4 for WT and n = 3 for Nptx2-/-. (H) Representative western blot images and quantification of GluA4
in forebrains of 6 month-old WT, hAPP and hAPP/Nptx2-/- mice. hAPP/Nptx2-/- mice show reduced GluA4 in brain. WT, n = 4; hAPP, n = 6; hAPP/
Nptx2-/-, n = 4. **p<0.01 by nonparametric one way ANOVA with Tukey post hoc test.
DOI: 10.7554/eLife.23798.011
The following figure supplements are available for figure 3:
Figure supplement 1. NPTX2 expression in amyloidosis mouse model.
DOI: 10.7554/eLife.23798.012
Figure supplement 2. Spontaneous sharp-wave ripples (SWRs) occur more frequently in hAPP/Nptx2-/- mice.
DOI: 10.7554/eLife.23798.013
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Figure 4. GluA4 levels are reduced in human postmortem AD brain. (A) Immunostaining of GluA4 demonstrates GluA4 is enriched on PV-IN in human
cortex. Data were collected from four cases including occipital gyrus and parietal gyrus. (B and C) Representative western blot images (B) and
quantification of GluA4 (C) in the frontopolar cortex (FPC), precuneus (PCU), middle frontal gyrus (MFG) and middle temporal gyrus (MTG) from
controls and AD subjects. GluA4 is significantly down-regulated in PCU and MFG of AD individuals. FPC: control, n = 7; AD, n = 8. PCU: control, n = 15;
Figure 4 continued on next page
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AD subjects there was a strong correlation with NPTX2 expression in both groups, albeit levels of
NPTX2 and GluA4 were lower in AD (Figure 4D). In young adult brain GluA4 expression did not cor-
relate with NPTX2 (Figure 4E and F), and NPTX2 expression was higher than in aged controls
(Figure 4G and H, and Figure 4—source data 1). These observations suggest that NPTX2 expres-
sion is reduced with normal aging and becomes a determinant of GluA4 expression independent of
overt cognitive disease. GluA4 is further reduced in AD by NPTX2 down-regulation in the context of
amyloidosis.
CSF NPTX2 provides a biomarker of brain NPTX2
To assess the relationship of NPTX2 to cognitive performance, we needed to establish a bioassay of
brain NPTX2 that could be measured in living subjects for whom behavioral test scores and other
information were available. We detected NPTX2 in CSF by WB, consistent with its natural secretion
at excitatory synapses and its potentially reversible association with glycoprotein networks that
uniquely surround PV-interneurons (Chang et al., 2010). CSF NPTX2 levels were reduced in AD sub-
jects (Figure 5A and B, and Figure 5—source data 1). CSF NPTX1 and NPTXR levels were also
reduced in the same CSF samples (Figure 5A and B, and Figure 5—figure supplement 1). NPTXR
in CSF was detected in WB as three bands corresponding to full length (60 kDa) and presumed
cleavage products at 45 kDa and 30 kDa and all three were reduced in AD CSF (Figure 5—figure
supplement 1). NPTX1 and NPTXR are widely expressed at excitatory synapses (Lee et al., 2017;
Xu et al., 2003) and their reduction in CSF despite preserved levels in AD brain suggests that their
expression in CSF arises from a discrete source. We determined that NPTX1 and NPTX2 in human
CSF are disulfide-linked oligomers (Figure 5—figure supplement 2A) consistent with their known
co-assembly in brain (Xu et al., 2003). Moreover, levels of CSF NPTX1 and NPTXR strongly correlate
with CSF NPTX2 in individual samples (Figure 5—figure supplement 2B). Since NPTX2 selectively
accumulates on PV-interneurons, we infer this as the major source of NPTX1, NPTX2, and NPTXR in
CSF.
We developed a sandwich ELISA to quantitate NPTX2 protein in CSF (Figure 5—figure supple-
ment 3) and confirmed close correspondence with levels measured by WB (Figure 5C). The mean
NPTX2 level in control CSF was 1067 pg/ml compared to 296 pg/ml in AD (Figure 5D). Consistent
with current standards to document a new biomarker (Noel-Storr et al., 2014) we screened a sec-
ond independent set of patient CSF samples by WB and ELISA and confirmed consistency of levels
in controls and reduction of NPTX2 in AD (Figure 5E, Figure 5—figure supplement 4, and Fig-
ure 5—source data 2). NPTX2 ELISA of samples from patients with MCI demonstrated reduction of
NPTX2 compared to controls (Figure 5F).
We compared the performance of NPTX2 to standard CSF biomarkers of AD. Receiver operating
characteristic (ROC) analysis revealed the specificity, sensitivity and accuracy of NPTX2 was similar to
Aß42 and superior to tau and p-tau for distinguishing controls from AD (Figure 5G–J). A ratio of tau
or p-tau divided by NPTX2 showed improved performance (Figure 5K and L). NPTX1/2/R levels did
not correlate with Aß42 but did positively correlate with tau and p-tau within individual AD patients
(Figure 5—figure supplement 5) and controls (NPTX2 vs tau, r = 0.4625, p=0.0002; NPTX2 vs
p-tau, r = 0.3607, p=0.0043, Pearson correlation coefficient analysis). This suggests that tau appear-
ance in CSF may be linked to NPTX2 and PV circuit function, however since they change in opposite
directions in AD and yet are positively correlated in both controls and AD their association appears
complex. Moreover, their complementarity in diagnostic performance suggests they detect distinct
processes.
Figure 4 continued
AD, n = 19. MFG: control, n = 9; AD, n = 16. MTG: control, n = 10; AD, n = 18. *p<0.05 by two-tailed t test. Data represent mean ± SEM. (D) GluA4
levels correlate with NPTX2 in both control and AD group. Pearson correlation coefficient analysis was performed. (E and F) GluA4 expression did not
correlate with NPTX2 in young adult brain. n = 10. Pearson correlation coefficient analysis was performed. (G and H) NPTX2 expression in young adult
brain was higher than in aged controls. Young, n = 12; Aged, n = 15. **p<0.01 by two-tailed t test. Data represent mean ± SEM.
DOI: 10.7554/eLife.23798.014
The following source data is available for figure 4:
Source data 1. Information of young healthy controls and aged healthy controls for brain analysis.
DOI: 10.7554/eLife.23798.015
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Figure 5. NPTX levels are reduced in CSF from individuals with clinically diagnosed AD. (A,B) Western blot assays of NPTX2, NPTX1 and NPTXR in
lumbar cerebrospinal fluid (CSF) from age-matched controls and patients with clinically diagnosed AD. AD patients show reduced NPTX2, NPTX1 and
NPTXR levels in CSF. Control, n = 36; AD, n = 30. (C) ELISA was developed to quantitate NPTX2 protein in CSF. NPTX2 assayed by ELISA corresponds
closely with levels defined by WB. n = 64. Pearson correlation coefficient analysis was performed. (D) ELISA shows significant reduction of NPTX2 in CSF
from patients with clinically diagnosed AD. Control, n = 36; AD, n = 28. (E) ELISA assay confirmed the reduction of NPTX2 in AD in second set of CSF
sample. n = 36 for control, n = 30 for AD. (F) CSF NPTX2 levels are significantly reduced in individuals with mild cognitive impairment (MCI) compared
with healthy controls. Control, n = 72; MCI, n = 17. (G–L) Receiver operating characteristic (ROC) curve analysis of CSF Ab42 (G), tau (H), p-tau181 (I),
NPTX2 (J), tau/NPTX2 (K) and p-tau/NPTX2 (L) as AD diagnostic biomarkers for distinguishing AD from control. Cut off values were determined by
maximizing Youden index value. ROC analysis of tau/NPTX2 indicates its diagnostic power is superior to NPTX2 alone, Aß42, tau or p-tau. AUC: area
under ROC curve. Control, n = 61–72; AD, n = 50–58. **p<0.01, ***p<0.001 by two-tailed t test. Data represent mean ± SEM.
DOI: 10.7554/eLife.23798.016
The following source data and figure supplements are available for figure 5:
Source data 1. Summary of human CSF analysis in Alzheimer’s disease (first cohort).
DOI: 10.7554/eLife.23798.017
Figure 5 continued on next page
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NPTX2 expression correlates with cognitive performance and measures
of hippocampal volume
Detailed cognitive data available for the second set of AD subjects revealed positive correlations
(p < 0.05) of NPTX2 with the Dementia Rating Scale (DRS) (Mattis, 1988), Digital symbol substitu-
tion (Wechsler, 1981), modified Wisconsin Card Sorting Task (Nelson, 1976), Block design Subtest
(Wechsler, 1974), Visual Reproduction Test [Russell Adaptation WMS; (Wechsler, 1945), semantic
verbal fluency [SVF (Borkowski et al., 1967), California verbal learning test [CVLT (Delis et al.,
1987) (Figure 6 and Table 1). By contrast, Aß42 levels correlated with SVF and CVLT, while tau and
p-tau did not correlate with these behavioral tests (Table 1). NPTX2 levels also correlated with hip-
pocampal occupancy (Heister et al., 2011), a measure of hippocampal volume, while Aß42, tau and
p-tau did not (Figure 6I and J, Table 1). Measures of hippocampal volume show robust associations
with cognitive performance and AD progression (Fjell et al., 2010; Heister et al., 2011; Jack et al.,
1999). These findings demonstrate the unique association of CSF NPTX2 expression with cognitive
performance and AD pathophysiology.
Discussion
The present study identifies NPTX2 down-regulation as an important mechanism in AD pathogenesis
that is closely linked to cognitive deterioration. The observed reductions of NPTX2 protein in human
brain and CSF, and the correlation of CSF NPTX2 with cognitive status and hippocampal volume
provide support for the notion that NPTX2 could be an informative biomarker for AD. The potential
value of NPTX2 as a biomarker is further advanced by the observation that NPTX2 appears ‘orthogo-
nal’ to Aß and tau since NPTX2 is not reduced as a direct consequence of Aß amyloid in mouse
models, appears independent of Aß in human asymptomatic AD (pre AD), and reductions of CSF
NPTX2 do not correlate with reduction of CSF Aß42 or increases of tau/p-tau. Because of the syner-
gistic effects of amyloidosis and NPTX2 down regulation, CSF levels of NPTX2 might distinguish sub-
jects who will be most responsive to amyloid reducing therapy. A recent study reported that CSF
NPTX2 may anticipate disease progression (Swanson et al., 2016). But the conclusion that NPTX2 is
simply an interesting biomarker in AD falls short of the opportunity to implicate a novel mechanism
that underlies cognitive failure. In particular, we propose that an important proximal cause of cogni-
tive decline in AD is failure of the adaptive function of pyramidal neurons to modify excitatory drive
of fast spiking parvalbumin (PV) interneurons.
The proposed mechanism builds upon prior studies that demonstrate NPTX2 is expressed in
pyramidal neurons as an IEG (Tsui et al., 1996), and is required for homeostatic scaling of pyramidal
neuron excitatory synapses on PV interneurons (Chang et al., 2010). One of the remarkable proper-
ties of NPTX2 is that it selectively accumulates at excitatory synapses on PV interneurons
(Chang et al., 2010). NPTX2 is a Ca2+ dependent lectin and appears to bind the glycoprotein net-
work that prominently surrounds PV interneurons (Chang et al., 2010; Tsui et al., 1996). NPTX2
also binds to postsynaptic AMPA receptors (Lee et al., 2017; O’Brien et al., 1999; Xu et al., 2003)
and acts to increase local accumulation of AMPA receptors and strengthen synapses. This action of
NPTX2 at excitatory synapses on PV interneurons is evident in vivo where genetic deletion of NPTX2
Figure 5 continued
Source data 2. Summary of human CSF analysis in Alzheimer’s disease (second cohort).
DOI: 10.7554/eLife.23798.018
Figure supplement 1. Reduction of NPTXR levels in lumbar cerebrospinal fluid (CSF) from individuals with AD.
DOI: 10.7554/eLife.23798.019
Figure supplement 2. Detection of NPTX in human CSF.
DOI: 10.7554/eLife.23798.020
Figure supplement 3. Development of NPTX2 ELISA assay.
DOI: 10.7554/eLife.23798.021
Figure supplement 4. Reduction of NPTX levels in second set of CSF from individuals with AD.
DOI: 10.7554/eLife.23798.022
Figure supplement 5. Positive correlation of NPTXs with CSF tau and p-tau.
DOI: 10.7554/eLife.23798.023
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results in a selective reduction of pyramidal neuron drive of PV interneurons in developing mouse
cortex (Gu et al., 2013). Nptx2-/- alone does not result in marked changes of PV interneuron function
as assayed by gamma oscillations in vivo or in acute slices, but Nptx2-/- combined with Nptxr-/-
resulted in a profound disruption of gamma oscillations and cognitive deficits in combination with a
reduction of GluA4 protein in PV-interneurons (Pelkey et al., 2015, 2016). GluA4 protein reduction
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Figure 6. NPTX2 expression correlates with cognitive performance and measures of hippocampal volume. (A) NPTX2 expression in CSF correlates with
cognitive function assayed by DRS in AD group. n = 30. p=0.0093 by Pearson correlation coefficient analysis. DRS: dementia rating scale. (B–D) No
correlation was observed between CSF Ab42 (B), tau (C) or p-tau181 (D) with DRS in AD group. n = 28. (E–H) NPTX2 expression in CSF correlates with
cognitive function assayed by WCST test (E), semantic verbal fluency test (F), VRT test (G) and CVLT test (H). n = 20–28. WCST: Wisconsin Card Sorting
Task; AFV: Semantic Verbal Fluency Test (‘Animals’, ‘Fruits’, ‘Vegetables’); VRT: Visual Reproduction Test; CVLT: California Verbal Learning Test.
Pearson correlation coefficient analysis was performed. (I) Representative images of human brain MRI imaging. (J) NPTX2 levels in CSF correlate with
hippocampal occupancy. n = 25 AD subjects. HOC: hippocampal occupancy.
DOI: 10.7554/eLife.23798.024
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was not associated with a reduced expression of Gria4 mRNA, TARP protein, parvalbumin immuno-
reactivity, or alteration of the perineuronal glycoprotein network. A hypothetical model was sug-
gested in which presynaptic NPTX2 is required to bind postsynaptic GluA4 and prevent receptor
turnover in conditions of altered activity consequent to Nptxr-/- (Pelkey et al., 2015, 2016).
To assess the notion that NPTX2 down-regulation in human brain is indicative of a disruption of
the pyramidal neuron-NPTX2-PV interneuron homeostatic mechanism we needed to identify a bio-
marker of PV-interneuron function that is dependent on NPTX2 expression and that could be quanti-
tatively assayed in human tissue samples. We confirmed in a mouse model that amyloid expression
(like Nptxr-/-) acts in synergy with Nptx2-/- to down-regulate GluA4 expression and results in antici-
pated changes of excitability and rhythmicity. These observations validated GluA4 as a biomarker of
NPTX2-dependent PV interneuron function in the context of amyloidosis. In human brain we found
GluA4 expression was reduced and correlated with NPTX2 expression in the same samples support-
ing the notion that GluA4 expression is dependent on NPTX2 expression in AD brain. Unexpectedly,
GluA4 and NPTX2 correlate within samples in both AD cases and in aged controls. This is notable
since in young adults NPTX2 and GluA4 expression do not appear to correlate within samples, and
NPTX2 appears higher in young brain than in aged controls. This age-dependence requires further
analysis, but suggests that GluA4 expression in PV interneurons becomes dependent on pyramidal
neuron expression of NPTX2 during normal aging, and GluA4 expression-PV interneuron function
become critically reduced in AD as NPTX2 expression is reduced. Additional studies are also neces-
sary to define the anatomic extent and possible progression of NPTX2 reduction beyond cortical
regions.
Both amyloid and NPTX2 result in reduced PV interneuron function and a consequent increase of
excitability of pyramidal neurons that are part of the reciprocal circuits with PV interneurons. How-
ever, the consequence of amyloid and NPTX2 down-regulation on pyramidal neuron-PV interneuron
circuits appear quite different. Amyloid reduces PV interneuron excitability by reducing expression
of the voltage sensitive sodium channel Nav1.1 (Verret et al., 2012). By contrast, NPTX2 down-reg-
ulation reduces pyramidal neuron excitatory drive of PV-interneurons. As an IEG, NPTX2 natural
expression is dynamic and limited to neurons that engage in information processing such as place
Table 1. Correlation analysis of CSF biomarkers with hippocampal size and clinical cognitive tests in AD subjects from second cohort.
Vs CSF NPTX2 Vs CSF ab42 Vs CSF tau Vs CSF p-Tau
n Pearson r p value n Pearson r p value n Pearson r p value n Pearson r p value
Average Hippocampal Occupancy 25 0.483 0.015 25 0.189 0.367 24  0.083 0.701 24 0.360 0.084
Dementia Rating Scale 30 0.467 0.009 28 0.225 0.249 27  0.137 0.497 27 0.296 0.134
Digit Symbol Substitution 24 0.446 0.029 23 0.127 0.565 22 0.095 0.673 22 0.043 0.849
Boston Naming Test 28 0.208 0.288 27 0.098 0.628 26  0.084 0.682 26 0.288 0.154
Phonemic Verbal Fluency Test 28 0.200 0.308 27  0.079 0.694 26  0.207 0.310 26 0.133 0.519
Semantic Verbal Fluency Test 28 0.385 0.043 27 0.396 0.041 26 0.121 0.557 26 0.036 0.863
Wisconsin Card Sorting Task_categories achieved 22 0.445 0.038 21 0.046 0.842 20  0.179 0.453 20  0.057 0.812
Wisconsin Card Sorting Task_perseverative errors 22  0.324 0.142 21 0.147 0.526 20 0.013 0.956 20  0.153 0.519
Visual Reproduction Test_immediate recall 24 0.432 0.035 23 0.149 0.497 22 0.325 0.140 22 0.292 0.187
Visual Reproduction Test_delayed recall 24 0.345 0.099 23 0.123 0.577 22  0.392 0.072 22  0.013 0.955
Block Design 28 0.446 0.017 27 0.082 0.683 26  0.111 0.590 26 0.004 0.984
Clock Drawing_command 28 0.337 0.079 27 0.040 0.845 26  0.119 0.563 26 0.087 0.673
Clock
Drawing_copy
28 0.011 0.955 27 0.106 0.600 26  0.246 0.225 26 0.161 0.434
California Verbal Learning
Test_list B recall
20 0.520 0.019 20 0.668 0.001 19 0.200 0.411 19  0.124 0.613
California Verbal Learning Test_recognition 20 0.109 0.647 20  0.096 0.687 19 0.046 0.851 19 0.221 0.364
Significant correlations (p < 0.05) are highlighted in yellow.
DOI: 10.7554/eLife.23798.025
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cells of the hippocampus [see for example the use of IEGs to detect place cells of the hippocampus
(Guzowski et al., 1999; Vazdarjanova et al., 2002). As a result of normal behavioral experience
NPTX2 expression establishes ‘informational’ circuits between pyramidal neurons and PV-interneur-
ons that will preferentially support the future activity of specific ensembles of neurons, for example,
during developmental wiring of the visual cortex (Gu et al., 2013). Since NPTX2 reduction in AD
occurs after accumulation of amyloid and parallels cognitive decline, we hypothesize that circuits can
adapt to the effects of amyloid if pyramidal neurons are able to maintain circuit-specific expression
of NPTX2. This model suggests that NPTX2 down-regulation is a ‘second hit’ for pyramidal neuron
PV-interneuron circuit dysfunction and cognitive failure in AD. Reciprocally, NPTX2 expression may
be considered a resilience factor.
Our model predicts that the combined action of amyloidosis and NPTX2 down-regulation will
produce a disruption of the dynamic recruitment of pyramidal neuron-PV interneuron circuits. Con-
sistent with these predictions brain activity is reportedly increased in MCI, early AD and aged con-
trols in regions termed the ‘default network’ (Buckner et al., 2005; Greicius et al., 2004;
Sperling et al., 2009) and dynamic connectivity within and between different resting state networks
measured by fMRI blood oxygen level dependent (BOLD) signals is reduced in AD (Thomas et al.,
2014). Since the capacity for gamma rhythmicity is thought to underlie dynamic connectivity
(Buzsa´ki and Wang, 2012; Engel et al., 2001), reduced fMRI BOLD signals may be the imaging cor-
relate of dysfunctional pyramidal neuron-PV interneuron circuits. Deficits of gamma oscillations are
associated with cognitive impairment in human cognitive disease including AD (Basar, 2013). It is
further notable that both NPTX2 down-regulation and fMRI functional connectivity similarly correlate
with clinical Dementia Rating scores (Thomas et al., 2014). Accordingly, we hypothesize that the fail-
ure of dynamic circuit properties is most consequential for cognitive dysfunction in AD.
Independent of NPTX2’s role in forming ‘informational’ circuits, increased activity consequent to
amyloid and NPTX2 reduction migh accelerate disease progression by placing increased demand on
alternative homeostatic mechanisms that weaken pyramidal neuron excitatory synapses, including
Arc (Shepherd et al., 2006) and Homer1a (Hu et al., 2010). Notably, the homeostatic mechanism
mediated by Arc generates Aß by enhancing secretase processing of APP (Wu et al., 2011). A feed-
forward mechanism of synaptic weakening is suggested by the observation that Arc is induced by
Aß activation of metabotropic glutamate receptors (Um et al., 2013; Wu et al., 2011). Arc is
reported to drive synapse elimination in the developing cerebellum (Mikuni et al., 2013). If Arc’s
action is increased consequent to amyloid and failure of pyramidal neuron-NPTX2-GluA4 homeosta-
sis it could contribute to increased Aß generation as well as weakening and loss of excitatory synap-
ses on pyramidal neurons. In this model, NPTX2 may be considered a ‘resilience factor’ that
maintains a balance of cell autonomous and circuit-based excitatory homeostasis.
Studies of DS brain suggest that NPTX2 down-regulation may contribute to cognitive deficits in
young individuals and disease progression. The availability of CSF and longitudinal follow up will be
required to assess this possibility.
Studies directed toward understanding the cause of NPTX2 down-regulation in AD and DS focus
attention on post-transcriptional mechanisms that impact mRNA stability. AD and DS share upregu-
lation of miRs that target the same 3’UTR sequence of Nptx2 mRNA. We hypothesize that NPTX2 is
normally regulated by miRs that may mediate the prominent delay in up-regulation of NPTX2 pro-
tein [for example after seizure (O’Brien et al., 1999), and that this process is dysregulated in AD
and DS. It is possible that biochemical pathways accentuated in aging or DS drive pathological miR
mechanisms. miR-96 has been implicated in normal differentiation of the auditory system
(Kuhn et al., 2011) and cell growth and oncogenesis (Guttilla and White, 2009; Xu et al., 2013).
miR-182 expression is induced by ß-catenin and in cancer cells contributes to invasiveness by down-
regulating RECK, an inhibitor of extracellular metalloproteases (Chiang et al., 2013; Hirata et al.,
2013). miR-1271, generated from an intron of Arl10, is human specific and targets multiple synaptic
genes including GABA synaptic protein gephyrin (Jensen and Covault, 2011). ARL10 protein is pre-
dicted to play a role in vesicular trafficking similar to ARFs (ADP-ribosylation factors)that are impli-
cated in trafficking synaptic proteins including BACE1 (Sannerud et al., 2011) and APOE receptor
LRP1 (Jiang et al., 2014). It remains a major goal to establish causal mechanisms controlling NPTX2
expression in human brain.
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Materials and methods
Mouse strains
Nptx2-/- mice in congenic C57BL/6J background were obtained from Mark Perrin’s lab. APPswe/
PS1DE9 transgenic mice (Borchelt et al., 1997) (here abbreviated hAPP) strain was obtained from
Dr. Philip Wong. hAPP mice with single copy of transgene were crossed with Nptx2-/- to generate
hAPP/Nptx2+/-, which were then crossed with Nptx2-/- to generate hAPP/Nptx2-/-. Similarly, WT
(C57BL/6J) were crossed to hAPP mice to generate hAPP/WT, which were crossed to WT to gener-
ate cohort. For both WT and Nptx2 deletion mice cohorts, we confirmed that ~50% of progeny of
the final cross carry the hAPP transgene, and this assured that mice carry a single copy of the trans-
gene. All procedures involving animals were under the guidelines of JHMI Institutional Animal Care
and Use Committee.
Human specimens
Human brain tissue of Alzheimer’s disease (AD) and asymptomatic AD (ASYMAD) was obtained from
the Johns Hopkins Brain Resource Center, which includes subjects from the Baltimore Longitudinal
Study of Aging. Subjects were recruited by the Clinical Core at Johns Hopkins Alzheimer’s Disease
Research Center (ADRC) from the community or from the cohort already enrolled in the Baltimore
Longitudinal Study on Aging. The assessment procedures have been coordinated by Joint Clinical
Core meetings that assure standardization of diagnostic procedures for annual medical, neurologic,
psychiatric and neuropsychological evaluations of all subjects. The Neuropathology Core arranges
and performs autopsies on clinically well-characterized participants who agreed to autopsy. Results
of neuropathological autopsies are then discussed on clinical-pathological conferences attended by
members of the Clinical and Neuropathology Cores. Human Down syndrome (DS) brain tissue and
control brains that went with those was obtained from two sources – one is University of Maryland
brain and tissue bank, and another is Dr. Benjamin Tycko at Taub Institute for Research on Alz-
heimer’s disease and the Aging Brain and Dr. Jerzy Wegiel at Institute for Basic Research in Staten
Island. Brain samples were lysed in RIPA buffer plus protease inhibitor cocktail at a dilution factor
1:50 for Western blot analysis.
Human cerebrospinal fluid (CSF) samples were obtained under IRB-approved protocols from par-
ticipants in the UCSD Alzheimer’s Disease Research Center. All participants were given informed
consent before taking part in the study. Human CSF samples were dissolved with SDS loading
buffer, and 12 ml of CSF were loaded to SDS-PAGE and subsequent Western blot. NPTX2 protein
levels in CSF were further quantitated by ELISA assay developed in current study. All CSF samples
were frozen at collection and assayed after first thaw. We noted that NPTX protein levels decreased
with multiple freeze thaw cycles. To validate the value of NPTX2 as a potential CSF biomarker of
AD, two independent cohorts of CSF samples were recruited and analyzed to confirm the finding.
Clinic information was blinded during experiment.
Reagents
Rabbit anti-NPTX1 and anti-NPTX2 were described previously (Cho et al., 2008; Xu et al., 2003).
Mouse anti-NPTX2 monoclonal antibody was made against GST NPTX2 N-terminus (a.a.1–220)
fusion protein. Antibody specificity was confirmed with the brain tissue of NPTX2-/- mice. Mouse
anti-Arc monoclonal antibody was described previously (Wu et al., 2011). All other antibodies are
from commercial companies. Sheep anti-NPTXR antibody is from R&D systems (Cat. Number:
AF4414; RRID: AB_2153869; Minneapolis, USA); mouse anti-APP N-terminus monoclonal antibody
22C11 is from Millipore (Cat. Number: MAB348; RRID: AB_94882; Massachusetts, USA); rabbit ant-
Egr1 (C-19) is from Santa Cruz (Cat. Number: sc-189; RRID: AB_2231020; Dallas, USA); mouse anti-
PSD95 is from Thermo Fisher Scientific (Cat. Number: MA1-046; RRID: AB_2092361; Halethorpe,
USA); mouse anti-gephyrin is from BD Transduction Laboratories (Cat. Number: 610584; RRID: AB_
397929, San Jose, USA); mouse anti-Homer1 is from Santa Cruz Biotechnology (Cat. Number: sc-
17842; RRID: AB_627742); rabbit anti-GluA4 is from Millipore (Cat. Number: MABN1109); mouse
anti-parvalbumin is from Sigma (Cat. Number: P3088; RRID: AB_477329; St. Louis, USA); mouse anti-
actin antibody is from Sigma (Cat. Number: A2228; RRID: AB_476697); ECLTM anti-mouse IgG HRP
is from GE Healthcare (Cat. Number: NA931V; Halethorpe, USA); ECLTM anti-rabbit IgG HRP is
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from GE Healthcare (Cat. Number: NA934V); donkey anti-sheep IgG HRP is from Santa Cruz (Cat.
Number: sc-2473; RRID: AB_641190).
Western blot substrate SuperSignal West Pico Luminol Enhancer Solution (Cat. Number:
1859675) and SuperSignal West Pico Stable Peroxide Solution (Cat. Number: 1859674) are from
Thermo Fisher Scientific.
Western Blot
Cultured cells or brain tissue were lysed with a modified RIPA buffer containing 1% Triton, 0.5% Na-
deoxycholate, 0.1% SDS, 50 mM NaF, 10 mM Na4P2O7, 2 mM Na3VO4, and protease inhibitor cock-
tail in PBS, pH 7.4. Protein extracts were separated by 4–12% SDS-PAGE, transferred to PVDF mem-
branes, blocked with 5% non-fat milk, and then probed with primary antibodies for overnight at 4˚C.
After washes with TBST (TBS with 0.1% Tween-20), membranes were incubated with HRP-conju-
gated secondary antibodies for 1 hr at room temperature (RT). Immunoreactive bands were visual-
ized by the enhanced chemiluminescent substrate (ECL, Pierce) on X-ray film and quantified using
the image software TINA (www.tina-vision.net). Actin and PSD95 were used as loading controls. Pro-
teins migrating similarly in SDS-PAGE gel were assayed on different blots without stripping.
NPTX2 ELISA
Preparation of His-tagged NPTX2 standard protein
Full length Nptx2-myc in pRK5 vector was used as a template. The N terminal fragment encoding
amino acid 1 to 201 was amplified with primers 5’ GCAAGGATCCCAAGCCCAGGATAACCC 3’ and
5’ CATGTCGACTCATGCACTGTTGCCTCTCTC 3’, and then cloned into pQE30 vector
(Qiagen, Germantown, USA) at sites of BamH1 and SalI. The protein was expressed in XL1-blue host
cells induced with 1 mM IPTG. The expressed NPTX2 fragment was purified with NI-NTA agarose
column (Qiagen), and the protein concentration was quantified with BCA kit (Thermo
Fisher Scientific).
ELISA assay
Basically, the operation follows the regular process of ELISA. Briefly, 0.5 mg of rabbit anti-NPTX2
antibody in 50 mM Na2CO3 buffer (pH 9.5) was coated to the ELISA plate (Nunc) at 4˚C for over-
night. Next day, after treating with blocking solution (5% BSA in PBS) for 1 hr at RT, 100 ul of the
series of diluted NPTX2 standard proteins or CSF samples were added into wells and incubated at
RT for 1 hr with constant shaking. After washing with TBS, 100 ul of biotinylated mouse anti-NPTX2
antibody was added and incubated at RT for 1 hr. Then, 100 ul of HRP conjugated streptavidin
(Biolegend, San Diego, USA) was added and incubated for 1 hr. After washing with TBS, 100 ul of
DAB substrate (Biolegend) was applied and incubated for half hour at RT in dark. In the end, 100 ul
of 4 M H2SO4 stopping solution was added and the absorbance was measured at 450 nm. The abso-
lute levels of NPTX2 in CSF were determined by the calculation based on standard curve.
Immunostaining of GluA4
Human neocortex was fixed by immersion in 10% formaldehyde in PBS (pH 7.4), and then embed-
ded in paraffin and sectioned to 5 mm thickness on slides. Sections were deparaffinized and hydrated
by incubating slides at 60˚C for 30 min and then transferred into Xylene. The paraffin was removed
after 3 changes of Xylene for 5 min. Then, slides were treated 3 min with sequential changes of
100%, 95%, and 70% ethanol and ddH2O for three times. Protein antigenicity was unmasked by the
treatment with 88% formic acid for 5 min. Slides were washed with ddH2O 3 times for 5 min each.
Then, sections were treated with blocking solution (10% horse serum, 0.4% Triton in TBS) for 1 hr at
RT and incubated with mouse anti-PV antibody (1:1000, Sigma) and rabbit anti-GluA4 antibody
(1:300, Millipore) at 4˚C for overnight. After three washes with TBS, tissue sections were incubated
with Alexa Fluo-conjugated secondary antibody at RT for 1 hr. Coverslips were mounted on glass
slides with ProLong Gold antifade reagent.
RNA extraction and quantitative PCR
Total RNA and small RNA were extracted by mirVana miRNA isolation kit (Ambion, Thermo Fisher
Scientific) according to the manufacturer’s protocol. Isolated RNA was treated with DNase to
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remove DNA (Turbo DNA-free kit, Ambion). One mg of isolated total RNA was then immediately
reverse-transcribed into cDNA using the SuperScript First-Strand Synthesis System for RT-PCR (Invi-
trogen, Thermo Fisher Scientific). Quantitative PCR was performed with a StepOne Plus machine
(Applied Biosystem, Thermo Fisher Scientific) using SYBR green ROX qPCR mastermix in a 96-well
optical plate. PCR cycling consists of 95˚C for 10 min, followed by 40 cycles of 95˚C for 30 s, 64˚C
for 30 s and 72˚C for 30 s. A melt curve was conducted to determine the specificity of PCR amplifica-
tion. Gapdh was served as an internal control to nomalize data. To assay the direct transcripts pre-
mRNA, primers were designed to bind with the intron of genes.
Assay Forward primer Reverse primer
Nptx2 pre-mRNA 5’ CTGCCCTCCCGCAAGTATAG 3’ 5’ ACCAGAGTGTCCCTACTCCC 3’
Nptx2 mRNA (Sato et al., 2003) 5’ CATCGAGCTGCTCATCAAC 3’ 5’ CTGCTCTTGTCCAAGGATC 3’
Arl10 pre-mRNA 5’ GTGGGGATGTCGGGAGAAAC 3’ 5’ GAAGACCGAAGGCACCAGAG 3’
Arl10 mRNA 5’ AGTTTGTGAGCGAGGTGGAT 3’ 5’ CTGGCTGCCAAGAGGAAAAC 3’
Gephyrin mRNA 5’ CCTCGTCCAGAATACCATCG 3’ 5’ CCACGTACTGTTCTGTCTTTGG 3’
Homer1 mRNA 5’ CAAGAACAGAGGGATTCTTTGA 3’ 5’ TGCGAAAAGCTTCTTGTTCA 3’
Gapdh 5’ AGAAGGCTGGGGCTCATTTG 3’ 5’ AGGGGCCATCCACAGTCTTC 3’
For analysis of miRNA abundance, 30 ng of isolated samll RNA was reverse-transcribed using
Taqman micoRNA reverse transcription kit (Applied Biosystems), and then subjected to Taqman
microRNA assays according to manufacturer’s protocol (Applied Biosystems) in StepOne Plus
machine. PCR cycling consists of 95˚C for 10 min, followed by 40 cycles of 95˚C for 15 s, 60˚C for 60
s. RNU48 served as an internal control to nomalize data.
Lentivirus preparation
Precursors of miR-96, miR-1271 and miR-182 were amplified by PCR from genomic DNA, and
inserted into PacI and NheI sites of lentiviral vector pSME2. Constructs were verified by sequencing.
The lentiviral production plasmids contain four constructs: the pSME2 lentiviral backbone plasmid
and three packaging plasmids pCMV-VSVG, pLP1 and pLP2. All constructs were transformed into
stbl3 competent cells (Life Technologies) and then prepared using a standard protocol of Qiagen
Maxiprep columns.
Lentivirus was produced and packaged in HEK293T cells. HEK293T cell line was purchased from
ATCC (Cat. Number: CRL-3216; RRID: CVCL_0063). No mycoplasma contamination was detected by
MycoAlert Mycoplasma Detection Kit (Cat. Number: LT07-218, Lonza, Allendale, USA). HEK293T
cells were grown in 175 cm2 flasks that were pre-coated with 0.01% poly L-lysine (PLL) solution and
maintained with DMEM containing 10% FBS. To improve transfection efficiency, 25 mM chloroquine
was added to the medium of cultured HEK293T cells when culture was 50% confluency, and transfec-
tion was performed one hour later. Cells were transfected using FuGene6 (Roche, New York, USA)
with the ratio of 1 mg plasmid DNA: 3 ml FuGene6. Eight hours after transfection, 10 mM sodium
butyrate was added to the medium to improve transfection efficiency. Culture medium was changed
at 24 hr after transfection and collected at 48 hr after medium change (the transfection efficiency
was monitored by GFP fluorescence). Virus particles were pelleted by centrifugation at 25,000 rpm
for 2 hr at 4˚C (Beckman SW 28 rotor). Virus was aliquot and stored at  80˚C for future use.
Neuronal culture
Primary neuronal cultures from embryonic day 17.5 (E17.5) mouse pups were prepared as described
previously (Chang et al., 2010). Cells were plated on 0.02% PLL-coated wells at a density of 50 
104 per well of 12-well plate, and infected with miRNA-expressing lentivirus immediately after plat-
ing. Seven days later, cells were harvested for RNA extraction or Western Blot assay.
DNA methylation assay - pyrosequencing
DNA from postmortem brains of AD patients and healthy control was extracted using QIAamp DNA
mini kit (Qiagen), then treated with bisulfite to convert cytosine residues to uracil, but leave
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methylated cytosine unaffected (EpiTect bisulfite kit, Qiagen). Bisulfite-treated DNA was amplified
by PCR using Qiagen DNA methylation assay PM00126406, then subjected to pyrosequencing to
determine the DNA methylation at Johns Hopkins University Genetic Resources Core Facility.
Luciferase reporter assay
Nptx2 3’UTR was amplified by PCR and inserted downstream of firefly luciferase in a reporter vector
pmirGLO (Promega, Madison, USA), which contains another luciferase, renilla luciferase, as an inter-
nal reference. Mutation of miR binding site on Nptx2 3’UTR was generated by QuickChange site-
directed mutagenesis kit using primers containing mutated nucleotids (Agilent Technologies, Santa
Clara, USA). Constructs were verified by sequencing.
HEK293 cells were co-transfected with pmirGLO/ WT or Mut Nptx2 3’UTR and miR mimics or
negative control siRNA (Qiagen) by Lipofectamine 2000 (Life Technologies). One day later, cells
were lysed and activities of firefly luciferase and renilla luciferase were assayed by Dual-luciferase
reporter assay system (Promega). The ratio of firefly luciferase to renilla luciferase activity repre-
sented the effects of miR mimics on Nptx2 3’UTR.
Slice electrophysiology
Interface electrophysiology experiments
Slices were prepared from wild type, NPTX2-/-, hAPP or hAPP/NPTX2-/- mice aged 3 to 4 months.
Mice were anaesthetized using isoflurane, decapitated and the brain was immediately immersed in
aCSF (at ambient temperature) aerated with 95% O2 and 5% CO2. The aCSF contained (in mM):
NMDG (135), KCl (1), KH2PO4, (1.2), MgCl2 (1.5), CaCl2 (0.5), glucose (10) and choline bicarbonate
(20). Horizontal slices (400 mm thick) containing the hippocampus were cut using a Leica VT1000S
vibrating microtome (Leica Microsystems, Germany) and were immediately placed into an interface-
style chamber (Warner Instruments, CT) containing humidified carbogen gas and perfused with aer-
ated aCSF (1–1.5 ml min 1) containing (in mM): NaCl (126), KCl (3), MgCl2 (2), CaCl2 (2), NaH2PO4
(1.25), glucose (10) and NaHCO3 (26). Slices were incubated for at least one hour before initiating
recording. Local field potentials were recorded from CA3 stratum pyramidale using glass pipettes
pulled from standard borosilicate glass (3–5 MW) and filled with aCSF. Signals were low-pass filtered
at 2 kHz and acquired at 10 kHz using an Axon Axopatch 1D amplifier (Molecular Devices, CA), digi-
tized using an Axon Digidata 1322A (Molecular Devices, CA) and captured on a computer running
pClamp 9 (Molecular Devices, CA). All Data were imported into Igor Pro 6 (Wavemetrics, OR) using
NeuroMatic (ThinkRandom, UK) and analysed using custom-written procedures. Sharp wave ripple
oscillation were recorded in drug-free conditions and then gamma oscillations were induced by
applying 25 mM carbachol (Sigma-Aldrich, MO) as described (Fisahn et al., 1998).
Data analysis
Sharp-wave ripples
SWRs were automatically detected using methods described elsewhere (Csicsvari et al., 1999;
Pelkey et al., 2015), but adapted for in vitro recordings. Extracellular recordings were digitally
band-pass filtered between 150 and 250 Hz to reveal SWRs, and the root mean square (RMS) of the
filtered recording was used for automatic detection. Periods where the RMS crossed a threshold of
4 SDs above the background were counted as SWR events in our detection algorithm. The nearest
peak to the threshold crossing was considered the centre of the SWR and 100 ms on either side of
the peak was extracted and the corresponding period of the unfiltered trace was transformed using
a Morlet wavelet function. The boundaries of the SWRs were defined as 2 SDs above the baseline
power (taken from the first 50 ms at 250 Hz) of the wavelet function. The peak frequency of the SWR
was taken from the wavelet transform, and the amplitude calculated by the peak-to-trough ampli-
tude of the band-pass filtered trace. The RMS of the filtered trace was calculated using the SWR
boundaries detected from the Wavelet transform, and those events with an average RMS of less
than 1.5 SDs above the background were rejected. To prevent contamination of SWR data by single
unit activity, all detected events of less than 10 ms duration were automatically rejected by our
detection algorithm.
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Gamma oscillations
Power spectra were generated from 400 s of unfiltered recordings during periods of gamma oscilla-
tions, and these were normalised by 1/f (after e.g. (Demanuele et al., 2007) and the z-score was cal-
culated as before (Pelkey et al., 2015). These normalised spectra were used to determine the peak
frequency, and power of gamma oscillations. Hypersynchronous bursts / population spikes during
gamma oscillations were automatically detected using the root mean square (RMS) of the filtered
recording. Traces were digitally high-pass filtered at 300 Hz to reveal single unit activity, and hyper-
synchronous bursts / population spikes during gamma oscillations were automatically detected using
the root mean square (RMS) of the filtered recording. Single units were identified as having ampli-
tude of least three standard deviations above the RMS, and the threshold for detecting hypersyn-
chronous bursts was set at 10 standard deviations above the RMS.
All data were tested for normality and then we used either parametric or nonparametric multiple
comparisons tests as appropriate.
Human behavioral tests (adapted from UCSD ADRC)
All behavioral tests were performed by UCSD ADRC. Summary of tests for which CSF NPTX2 levels
showed a correlation of p < 0.05 (Table 1).
Dementia Rating Scale (Mattis, 1988)
The DRS is a standardized, 144-point mental status examination with subscales for Attention (37
points), Initiation and Perseveration (37 points), Conceptualization (39 points), Construction (six
points), and Memory (25 points). The DRS was administered according to the standardized instruc-
tions with the exception that every item was administered to every participant.
Digit symbol substitution subtest (WAIS-R; [Wechsler, 1981])
In this task, subjects are presented with a key, which associates unfamiliar symbols with the numbers
1 through 9. They are then asked to use the key to draw the appropriate symbols below a series of
their associated numbers as quickly as possible for 90 s.
Semantic verbal fluency (Borkowski et al., 1967)
The subject is asked to generate orally as many different kinds of animals, fruits, and vegetables as
possible within a given time limit. For each category, the subject is allowed one minute to generate
items. The subject’s score is the total number of items correctly named for the three categories. Per-
severations and intrusion errors are also noted. Although fluency tests are sensitive to language dys-
functions and deterioration of semantic knowledge, they can also reflect an individual’s capacity to
retrieve information from semantic memory. If other language abilities, such as confrontation naming
and comprehension are intact, impaired fluency may be due to an inability to initiate systematic
retrieval of information in semantic storage (Butters et al., 1987).
Modified Wisconsin Card Sorting Test (WCST) (Nelson, 1976)
The Wisconsin Card Sorting Test is widely accepted as a measure of abstracting ability, which is sen-
sitive to frontal lobe pathology. In Nelson (1976) modified version of the test, subjects must sort 48
response cards on which are printed one to four symbols (triangle, star, cross, or circle) in one of
four colors (red, green, yellow, or blue), according to the proper symbol or color as indicated by a
stimulus card. The test continues until six sorts (principles) are achieved or until all 48 response cards
have been sorted. The number of sorts achieved, the total number of correct card placements, the
number of perseverative errors, and the number of non-perseverative errors is recorded.
Block design subtest (WISC-R; [Wechsler, 1974])
For this constructional task, the subject is presented with four or nine red and white blocks and
asked to construct replicas of 11 designs. The blocks are red on two sides, white on two sides, and
half white, half red on two sides. The seven four block designs have either 60 or 75 s limits; the three
nine block designs, two minute limits. The subject’s score depends both upon accuracy and speed.
For the first two block designs, the subject copies the examiner’s block constructions; for the
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remaining nine designs, he copies two-dimensional pictures of the designs. The Block Design Test is
sensitive to the early cognitive decline that occurs in either cortical or subcortical dementia.
Visual reproduction test (Russell Adaptation WMS; [Wechsler, 1945])
This test provides a measure of memory for geometric forms. On each of three trials, the subject
must reproduce a complex geometric figure from memory immediately following a 10 s study
period. Three increasingly complex stimuli containing from 4 to 10 components are presented on
successive trials. As a measure of long-term retention, the subjects are asked after 30 min of unre-
lated testing to again reproduce the figures from memory. A delayed recognition test was also
administered, which consists of 18 target items and 18 distractor items. Target items consist of the
four complete original designs and 14 partial replications of the four original designs. Finally, the
subject is asked to simply copy the stimulus figures in order to assess any visuoperceptual dysfunc-
tion that may be contaminating visual memory performance. The subject’s reproductions are scored
for the number of components present from the original stimulus drawings.
California verbal learning test (Delis et al., 1987)
The CVLT is a list-learning task that assesses multiple cognitive parameters associated with learning
and memory, thereby providing an evaluation of the learning process as well as a measure of how
much information is acquired and retained. On each of 5 trials, 16 words are presented orally at the
rate of one word per second and immediate free recall of the words is elicited. The 16 words consist
of four words from each of four semantic categories. Immediately following the fifth presentation/
recall trial with the original list, a single presentation/recall trial is presented using a new list (list B)
of 16 words. The subject is then asked to again recall the original 16 words, and then to recall the
same words when provided with semantic cues. Following a 20 min delay that is filled with unrelated
neuropsychological testing, free recall and cued recall of the original 16 word list is again elicited.
Finally, a yes/no recognition test is administered consisting of the original 16 words and 28 randomly
interspersed distractor words.
Tests for which none of the CSF biomarkers reached p<0.05 included Mini Mental Status Exam
(MMSE), Blessed Information-Memory-Concentration Test, Boston Naming Test, Clock Drawing
Command, Clock Drawing copy. Tau shows correlation (p=0.012) for CERAD (Consortium to Estab-
lish a Registry for Alzheimer’s Disease) trial three recall only.
Mini-Mental state examination (Folstein et al., 1975)
The MMSE is a structured scale that briefly assesses orientation to place, orientation to time, regis-
tration, attention and concentration, recall, language, and visual construction. It is scored in terms of
the number of correctly completed items with lower scores indicative of poorer performance and
greater cognitive impairment. The total score ranges from 0 to 30 (perfect performance).
Phonemic fluency test (Borkowski et al., 1967)
On the letter fluency test, the subject is asked to generate orally as many words as possible that
begin with the letters ‘F,’ ‘A,’ and ‘S,’ excluding proper names and different forms of the same
word. For each letter, the subject is allowed one minute to generate words. Performance is mea-
sured by the total number of correct words produced to the three letters. Perseverations (i.e., repeti-
tions of a correct word) and intrusions (i.e., words not beginning with the designated letter) are
noted.
Blessed Information-Memory-Concentration test (Blessed et al., 1968)
The test consists of 26 items that assess aspects of orientation (personal information, time, and
place), memory (remembering new and remote information), and concentration (counting back-
wards, saying the months of the year backwards). The IMC test is scored in terms of errors (0 (per-
fect performance) to 33), with higher scores reflecting poorer performance and greater cognitive
impairment.
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Boston naming test (Kaplan et al., 1983)
The UCSD abbreviated version of this test requires the subject to name 30 objects depicted in out-
lined drawings. The drawings are graded in difficulty, with the easiest drawings presented first. If a
subject encounters difficulty in naming an object, a stimulus or phonemic cue is provided. The num-
ber of spontaneous and cued correct responses, perceptual errors, circumlocutions, paraphasias,
and perseverations are used to evaluate the subjects’ language performance. In addition to provid-
ing quantitative measures of naming ability with and without semantic cueing, the BNT also yields
valuable information concerning the processes underlying a given patient’s naming errors.
Clock drawing command and copy tests (Goodglass and Kaplan, 1972)
In the first part of this visuoperceptual constructional task, the subject is required to draw a clock
with numbers and to set the hands at ten past eleven. In the second part of the test, the subject
attempts to copy a picture of a clock with the hands set at ten past eleven. Rouleau and colleagues
(Rouleau et al., 1992) have developed a 10-point score system for grading an individual’s overall
performance on the drawing-to-command and copying conditions. A maximum of 2 points is given
for the integrity of the clockface; a maximum of 4 points for the presence and sequencing of the
numbers; a maximum of 4 points for the presence and placement of the hands.
CERAD Word-List learning task (Welsh et al., 1992)
If it is judged that an overwhelming majority of subjects are able to read, the CERAD Word-List
Learning Test will be administered since this test has been widely and effectively used for the assess-
ment of dementia. This task consists of immediate free recall of a 10-item word list assessed over
three separate learning trials. The subject is asked to read aloud 10 printed words at a rate of one
every two seconds. Immediately following the presentation of the list, the subject is asked to recall
as many of the words as possible. Two additional learning trials are immediately administered follow-
ing the same procedure. After a delay of five to eight minutes filled with unrelated testing, the sub-
ject is again asked to recall as many of the words from the 10-item list as he or she can (i.e., delayed
recall). A savings score is calculated by dividing the number of words correctly recalled in the delay
condition by the number of words recalled on the third learning trial. A delayed word-list recognition
task is also administered. In this yes/no recognition task, the subject must identify the original 10
items on a list of these words intermixed with 10 distractor words. As with the Fuld Object Memory
Test, the CERAD Word-List Learning Task provides a number of memory measures that are effective
for detecting early dementia and for differentiating among different forms of dementia.
Human brain imaging
Imaging was performed using 3D T1-weighted MRI sequences based on the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) (Jack et al., 2008). For segmentation, NeuroQuantTM a probabilistic-
atlas based volumetric MRI software package (CorTechs Labs, Inc, La Jolla, CA), was used to derive
regional volumes of the hippocampus and temporal horn using methods previously described
(Brewer et al., 2009). The hippocampal occupancy score (Heister et al., 2011) is a measure of hip-
pocampal volume divided by the sum of hippocampal and temporal horn volumes and is intended
to account for regional ex-vacuo expansion of the fluid space adjacent to the hippocampus typically
seen when the hippocampus atrophies.
Receiver Operating Characteristic curve analysis
To evaluate the diagnostic value of CSF biomarkers, receiver operating characteristic (ROC) curve
analysis (Metz, 1978) was performed. ROC curve was created by plotting the true positive rate (sen-
sitivity) against the false positive rate (100-specificity) for different cut-off points. Each point on the
ROC curve represented a sensitivity/specificity pair corresponding to a particular threshold. The area
under the ROC curve (AUC) indicated how well two diagnostic groups can be distinguished. Accu-
racy was defined as the proportion of true results in the whole population [(true positive + true nega-
tive)/(true positive + false positive + true negative + false negative)]. For each CSF biomarker, the
cut-off point which maximizing Youden index (sensitivity + specificity  1)(Youden, 1950) was
selected to calculate the accuracy of a CSF biomarker as a diagnostic test.
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Statistical analysis
We used GraphPad PRISM version 5 (RRID: SCR_002798) to perform statistical analyses. Two-tailed t
test was employed to analyze difference between two groups. Correlation analysis were performed
by Pearson correlation coefficient. Sample sizes of human specimens were estimated by power anal-
ysis using G*Power (RRID: SCR_013726).
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